Phase II clinical study of CIM331 (hemodialysis)
Phase 2
- Conditions
- Pruritus in dialysis patients
- Registration Number
- JPRN-jRCT2080222909
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
(1) Patients who receive hemodialysis three times a week.
(2) Patients who have been treated with systemic therapy or topical therapy for pruritus and who are inadequately controlled by them, or patients who have been treated with nalfurafine hydrochloride for pruritus.
Exclusion Criteria
Patients who are judged to be inadequate for this study participation by investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does CIM331 target to alleviate pruritus in hemodialysis patients?
How does CIM331 compare to standard-of-care treatments for uremic pruritus in dialysis patients?
Are there specific biomarkers that predict CIM331 efficacy in hemodialysis-induced pruritus?
What adverse events are associated with CIM331 in phase II hemodialysis trials and how are they managed?
What are the potential combination therapies involving CIM331 for managing refractory pruritus in dialysis patients?